Indefinite Delivery Contract SPE2DB24D9801

The federal contract IDV award is a single-award indefinite delivery contract (IDC) between the Defense Logistics Agency (DLA) and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, awarded on June 6, 2024, provides the DLA with a vehicle to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to meet the recurring medical supply needs of military health facilities worldwide. The contract, under the SPE2DB program, has an ultimate completion date of December 31, 2025.

Through this IDC, DMS Pharmaceutical Group provides the DLA and Department of Defense (DoD) with a diverse selection of medications, including branded and generic prescription drugs, over-the-counter medicines, biologics, and medical consumables across multiple therapeutic classes. The company's pharmaceutical offerings span common and specialized products, such as flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications for rare diseases. The contract enables the DLA to efficiently procure these essential pharmaceutical supplies to support the diverse medical requirements of military personnel and their dependents at DoD healthcare facilities globally.